Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 469

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 469
---
 expenses were $ 529, consisting of $ 13of prepaid R&D clinical costs, $ 149of prepaid insurance, and $ 367of other prepaid costs.

8.Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ 
 ​ | ​ |              ​ 
 March 31, 2025 | ​ | ​ |                 ​ 
 December 31, 2024 |
|:------------------------------------|:--|:--|---------------:|:--|:--|------------------:|
| Accounts payable                    | ​ | $ |              4 | ​ | $ |             1,434 |
| Accrued research projects           | ​ |   |             70 | ​ |   |                64 |
| Accrued compensation and benefits   | ​ |   |            606 | ​ |   |               565 |
| Accrued professional fees and other | ​ |   |            519 | ​ |   |             1,909 |
| Total                               | ​ | $ |          1,199 | ​ | $ |             3,972 |

9. Royalty Purchase and Sale Agreement During the fourth quarter of 2023, Cara, through its wholly-owned subsidiary Cara Royalty Sub, entered into the Purchase and Sale Agreement (the “Original HCR Agreement”) by and among Cara Royalty Sub, HCRX Investments HoldCo, L.P. (“HCRX”) and HealthCare Royalty Partners IV, L.P. (“HCR IV” and together with HCRX, “HCR”), pursuant to which Cara Royalty Sub sold, or agreed to sell, to HCR certain of its rights to receive royalty payments (the “Royalties”), due and payable to Cara Royalty Sub (as assignee of Cara) under the Maruishi Agreement and Vifor Agreement No. 2. (as defined below), collectively the Covered License

F- 115

TVARDI THERAPEUTICS, INC. (Formerly Cara Therapeutics, Inc.) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (amounts in thousands, except share and per share data) (unaudited)

Agreements, in exchange for up to $. Cara has retained all of its rights, title and interest in, to and under the Covered License Agreements that relate to any non-intravenous formulation of difelikefalin.

Under the terms of the